Cargando…
Is It Time to Revisit Remdesivir Use for Severe COVID-19?
How to cite this article: Taggarsi DA. Is It Time to Revisit Remdesivir Use for Severe COVID-19? Indian J Crit Care Med 2022;26(9):983–984.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Jaypee Brothers Medical Publishers
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492745/ https://www.ncbi.nlm.nih.gov/pubmed/36213702 http://dx.doi.org/10.5005/jp-journals-10071-24317 |
| _version_ | 1784793546138583040 |
|---|---|
| author | Taggarsi, Dipali Anand |
| author_facet | Taggarsi, Dipali Anand |
| author_sort | Taggarsi, Dipali Anand |
| collection | PubMed |
| description | How to cite this article: Taggarsi DA. Is It Time to Revisit Remdesivir Use for Severe COVID-19? Indian J Crit Care Med 2022;26(9):983–984. |
| format | Online Article Text |
| id | pubmed-9492745 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Jaypee Brothers Medical Publishers |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94927452022-10-07 Is It Time to Revisit Remdesivir Use for Severe COVID-19? Taggarsi, Dipali Anand Indian J Crit Care Med Editorial How to cite this article: Taggarsi DA. Is It Time to Revisit Remdesivir Use for Severe COVID-19? Indian J Crit Care Med 2022;26(9):983–984. Jaypee Brothers Medical Publishers 2022-09 /pmc/articles/PMC9492745/ /pubmed/36213702 http://dx.doi.org/10.5005/jp-journals-10071-24317 Text en Copyright © 2022; The Author(s). https://creativecommons.org/licenses/by-nc/4.0/© The Author(s). 2022 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Editorial Taggarsi, Dipali Anand Is It Time to Revisit Remdesivir Use for Severe COVID-19? |
| title | Is It Time to Revisit Remdesivir Use for Severe COVID-19? |
| title_full | Is It Time to Revisit Remdesivir Use for Severe COVID-19? |
| title_fullStr | Is It Time to Revisit Remdesivir Use for Severe COVID-19? |
| title_full_unstemmed | Is It Time to Revisit Remdesivir Use for Severe COVID-19? |
| title_short | Is It Time to Revisit Remdesivir Use for Severe COVID-19? |
| title_sort | is it time to revisit remdesivir use for severe covid-19? |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492745/ https://www.ncbi.nlm.nih.gov/pubmed/36213702 http://dx.doi.org/10.5005/jp-journals-10071-24317 |
| work_keys_str_mv | AT taggarsidipalianand isittimetorevisitremdesiviruseforseverecovid19 |